Original from: GlobeNewswire
Mainz Biomed N.V. (NASDAQ:MYNZ) (¡°Mainz Biomed¡± or the ¡°Company¡±), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company¡¯s flagship product, ColoAlert® in Italy. TomaLab is one of Italy¡¯s premier biotechnology laboratories and is based in Milan. The partnership signifies a major step forward in enhancing colorectal cancer screening and diagnostics within the Italian healthcare system as it enables the implementation of ColoAlert® into Italy's robust healthcare framework, providing patients with access to a cutting-edge diagnostic solution that combines convenience with clinical excellence.
"TomaLab is the ideal partner to bring our pioneering product to Italy given its state-of-the-art facilities and commitment to innovative healthcare solutions," said Guido Baechler, CEO of Mainz Biomed. "This collaboration aligns with our mission to make advanced diagnostic tools widely accessible, improving early detection rates and ultimately saving lives."
ColoAlert®, a highly effective and user-friendly at-home detection test, offers a non-invasive, highly sensitive test for early detection of colorectal cancer (CRC) and precancerous lesions. By utilizing advanced DNA technology, ColoAlert®detects cancerous and precancerous conditions with greater precision than traditional non-invasive screening methods, making it a pivotal tool in the fight against one of the most common and deadly cancers worldwide.
The launch of ColoAlert® in Italy comes at a critical time, given the current landscape where colorectal cancer ranks as the second most common cancer in the country. Furthermore, there's a concerning trend of rising incidence rates among young adults. Early detection remains a key factor in improving survival rates, and with ColoAlert®'s advanced diagnostic capabilities, more individuals will have timely access to life-saving screenings.
"We are thrilled to collaborate with Mainz Biomed to incorporate ColoAlert® into our laboratory procedures," stated Dr. Riccardo Manca, CEO of TomaLab. "This partnership underlines our dedication to embracing cutting-edge technologies that enhance patient care and outcomes."
